loviride has been researched along with Hepatitis B Virus Infection in 1 studies
loviride: structure given in first source; inhibits virion and recombinant HIV-1 reverse transcriptase
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy and safety of lamivudine in persons coinfected with human immunodeficiency virus (HIV) type 1 and hepatitis B virus (HBV) were examined in the CAESAR study, a randomized placebo-controlled trial assessing the addition of lamivudine (150 mg 2x/day) or lamivudine (150 mg 2x/day) plus loviride (100 mg 3x/day) to zidovudine-containing background antiretroviral treatment." | 9.09 | Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. ( Atkins, M; Barrett, C; Cooper, DA; Dore, GJ; Goh, LE; Thakrar, B, 1999) |
| "The efficacy and safety of lamivudine in persons coinfected with human immunodeficiency virus (HIV) type 1 and hepatitis B virus (HBV) were examined in the CAESAR study, a randomized placebo-controlled trial assessing the addition of lamivudine (150 mg 2x/day) or lamivudine (150 mg 2x/day) plus loviride (100 mg 3x/day) to zidovudine-containing background antiretroviral treatment." | 5.09 | Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. ( Atkins, M; Barrett, C; Cooper, DA; Dore, GJ; Goh, LE; Thakrar, B, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dore, GJ | 1 |
| Cooper, DA | 1 |
| Barrett, C | 1 |
| Goh, LE | 1 |
| Thakrar, B | 1 |
| Atkins, M | 1 |
1 trial available for loviride and Hepatitis B Virus Infection
| Article | Year |
|---|---|
Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee.
Topics: Acetamides; Acetophenones; Adult; Aged; Anti-HIV Agents; Antiviral Agents; Disease Progression; Dise | 1999 |